G. Richardson

发表

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Marc Peeters, Bart Neyns, E. Van Cutsem, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.

M. Quinn, M. Friedlander, D. Rischin, 2004, Gynecologic oncology.

Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

A. Welm, R. Daly, Sung-Young Shin, 2021, Breast Cancer Research.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

F. Saad, A. Stopeck, D. Yardley, 2012, European journal of cancer.

Smoking Cessation after Successful Treatment of Small-Cell Lung Cancer Is Associated with Fewer Smoking-related Second Primary Cancers

M. Tucker, D. Venzon, D. Ihde, 1993, Annals of Internal Medicine.

Hyponatremia of malignancy.

G. Richardson, J. Shapiro, 1995, Critical reviews in oncology/hematology.

The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study

P. Gibbs, J. Tie, H. Wong, 2017, Asia-Pacific journal of clinical oncology.

Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent.

P. Gibbs, J. Tie, H. Wong, 2016, Clinical colorectal cancer.

A prospective study of patients with lung cancer and hyponatremia of malignancy.

D. Venzon, B. Johnson, J. Chute, 1997, American journal of respiratory and critical care medicine.

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.

M. Ranson, J. von Pawel, U. Gatzemeier, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The biology of lung cancer.

B. Johnson, G. Richardson, 1993, Seminars in oncology.

Treatment and outcomes of metastatic colorectal cancer in Australia: defining differences between public and private practice

P. Gibbs, H. Wong, B. Tran, 2015, Internal medicine journal.

Adult acute leukaemia--a retrospective study of 66 consecutive patients.

G. Brodie, G. Richardson, P. Briggs, 1997, Australian and New Zealand journal of medicine.

Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.

Stephen B. Fox, R. Tothill, J. Desai, 2021, JCO precision oncology.

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

B. Monk, A. Tinker, A. Oza, 2021, The Lancet. Oncology.

Evaluation of the Simplified Comorbidity Score (Colinet) as a prognostic indicator for patients with lung cancer: a cancer registry study.

G. Giles, D. Ball, L. Irving, 2013, Lung cancer.

Phase I I C omparator S tudy o f O ral V ersus I ntravenous Topotecan i n P atients W ith C hemosensitive S mall-Cell Lung C ancer

M. Ranson, U. Gatzemeier, J. Pujol, 2011 .

Improved haematopoietic recovery following transplantation with ex vivo‐expanded mobilized blood cells *

P. Simmons, J. Seymour, D. Haylock, 2004, British journal of haematology.

Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour.

P. Gibbs, J. Tie, H. Wong, 2016 .

Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.

P. Francis, D. Rischin, H. Prince, 2002, Cytotherapy.

CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy.

D. Rischin, H. Prince, P. Simmons, 2002, Cytotherapy.

Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study

D. Rischin, J. Seymour, M. Wolf, 2000, Bone Marrow Transplantation.

Docetaxel effectively mobilizes peripheral blood CD34+ cells

D. Rischin, J. Seymour, M. Wolf, 2000, Bone Marrow Transplantation.

Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.

P. Francis, J. Zalcberg, M. Millward, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.

F. Saad, A. Stopeck, D. Yardley, 2016, European journal of cancer.

Denosumab versus zoledronic acid (ZA) for the treatment of bone metastases: An integrated analysis of results from 2 randomized, double-blind, phase 3 trials

Chunlei Ke, Alison T Stopeck, David H. Henry, 2011 .

“Cancer 2015”: A Prospective, Population-Based Cancer Cohort—Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic

David M. Thomas, John J. McNeil, Brett Doble, 2015, Journal of personalized medicine.

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Ignace Vergote, Beth Y Karlan, Christian Marth, 2016, Gynecologic oncology.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial

B. Monk, B. Karlan, A. Oza, 2014 .

Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.

B. Monk, B. Karlan, A. Oza, 2015 .

Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer

P. Francis, M. Millward, D. Rischin, 1999, Bone Marrow Transplantation.

A phase II trial of paclitaxel and epirubicin in advanced breast cancer

M. Millward, D. Rischin, M. Boyer, 2000, British Journal of Cancer.

Effect of treatment on the immunological status of women with advanced breast cancer.

M. Baum, L. Hughes, T. Priestman, 1979, British Journal of Cancer.

Levamisole: a double blind immunological study.

R. Whitehead, L. Hughes, G. Richardson, 1982, Anticancer research.

Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary

R. Tothill, D. Etemadmoghadam, A. deFazio, 2023, Journal for ImmunoTherapy of Cancer.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

B. Monk, B. Karlan, A. Oza, 2014, The Lancet. Oncology.

Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years.

R. Tothill, S. Fox, D. Etemadmoghadam, 2019, Journal of Clinical Oncology.

Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial

B. Monk, A. Tinker, A. Oza, 2019, Gynecologic Oncology.

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

K. Friedrichs, S. Chan, T. Pintér, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer.

S. Clarke, D. Goldstein, M. Millward, 2001, Lung cancer.

Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer.

J. Zalcberg, M. Millward, M. McKeage, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years.

P. Okunieff, D. Venzon, B. Johnson, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer.

B. Solomon, M. Millward, D. Ball, 2003, Lung cancer.

Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs.

D. Venzon, B. Johnson, D. Ihde, 1993, Archives of internal medicine.

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

J. Desai, B. Solomon, M. Brown, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.

B. Karlan, A. Oza, D. Provencher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

D. Dunlop, J. von Pawel, U. Gatzemeier, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A PILOT STUDY OF PREOPERATIVE AND POSTOPERATIVE CHEMOTHERAPY IN PATIENTS WITH OPERABLE GASTRIC CANCER: AUSTRALASIAN GASTROINTESTINAL TRIALS GROUP STUDY 9601

V. Gebski, D. Goldstein, H. Dhillon, 2007, ANZ journal of surgery.

Is There a Relationship Between Frequency of Port-Care Maintenance and Related Complications in Patients With Cancer?

T. Lang, G. Richardson, Joseph G O'Sullivan, 2022, JCO oncology practice.

Paclitaxel-induced "recall" soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb.

G. Richardson, J. Shapiro, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.

P. Gibbs, J. Desai, J. Tie, 2016, Clinical colorectal cancer.

Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors

J. Desai, B. Solomon, M. Brown, 2016 .

Bisphosphonate infusions: patient preference, safety and clinic use

K. Pittman, M. Schou, G. Richardson, 2004, Supportive Care in Cancer.

Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer

P. Gibbs, Y. Kanjanapan, R. Wong, 2020, Breast Cancer Research and Treatment.

JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer.

B. Monk, J. Ledermann, M. Birrer, 2019, Journal of Clinical Oncology.

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors

H. Mamdani, J. Baranda, D. Uprety, 2023, Cancers.

Sequential staging systems for small-cell lung cancer.

G. Richardson, 1994, Archives of internal medicine.

Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.

V. Ganju, J. Coward, G. Richardson, 2019, Journal of Clinical Oncology.

Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis.

S. Novello, M. Krzakowski, T. Ciuleanu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention of infection in a patient with chronic idiopathic neutropenia undergoing coronary bypass surgery with peri-operative G-CSF.

G. Fetherston, G. Richardson, J. Shapiro, 1996, The Australian and New Zealand journal of surgery.

Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?

P. Gibbs, L. Lipton, J. Tie, 2019, Internal medicine journal.

A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.

A. Hui, U. Vaishampayan, S. Williamson, 2019, Journal of Clinical Oncology.

Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia

P. Gibbs, J. Desai, J. Tie, 2015, Asia-Pacific journal of clinical oncology.

Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine.

David M. Thomas, S. Fox, L. Lipton, 2015, Drug discovery today.

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

S. Chan, T. Pintér, I. Bodrogi, 1999, Journal of Clinical Oncology.

Evaluation of the Simplified Comorbidity Score (Colinet) as a prognostic indicator for patients with lung cancer: a cancer registry study.

G. Giles, D. Ball, L. Irving, 2013, Lung cancer.

137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors

A. Tolcher, X. Wang, S. Fischkoff, 2021, Annals of Oncology.